NCI To Voluntarily Spends $196 Million On Breast Cancer; Will Require Reallocation
In Brief: Reginald Ho Assumes ACS Presidency; Board Calls On NCI To Fully Fund ASSIST Program
FDA Proposes Office For Patients With Life Threatening Disease
DCT Board Sends Letter Opposing Bill Requiring Research On RU 486
DCPC Bard Approves Concepts For New Grant Programs
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs









